Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

LDL-C Management Trends in ASCVD Patients
LDL-C Management Trends in ASCVD Patients
Heart Matters
LDL-C Management Trends in ASCVD Patients
- Keith C. Ferdinand, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Matters
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Heart Matters
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
Heart Matters
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Heart Matters
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Heart Matters
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
- Chisato Izumi, MD, PhD
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
Heart Matters
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
- Léna Rivard, MD
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
Heart Matters
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD

Programs

Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
Heart Matters
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Heart Matters
No benefit of routine spironolactone post-MI
- Sanjit Jolly, MD
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Heart Matters
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Scott Solomon, MD
- Mikhail Kosiborod, MD
0.50 credits
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
MinuteCE®
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
0.75 program credits
- Brian P. McDonough, MD, FAAFP
- Barry Greenberg, MD
- Neil Skolnik, MD
- Karina Brown, BSN, RN
0.75 program credits
Partnering with Patients: Building Effective Communication and Support in HF Care
Partnering with Patients: Building Effective Communication and Support in HF Care
MinuteCE®
Partnering with Patients: Building Effective Communication and Support in HF Care
0.75 program credits
- Brian P. McDonough, MD, FAAFP
- Barry Greenberg, MD
- Melissa Mclenon, DNP, ACNP-BC
0.75 program credits
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
MinuteCE®
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
1.75 program credits
- Scott Kaatz, DO, MSc, FACP, SFHM
1.75 program credits
Right from the Onset: DVT Diagnosis, Management
Right from the Onset: DVT Diagnosis, Management
MinuteCE®
Right from the Onset: DVT Diagnosis, Management
1.75 program credits
- Bruce L. Davidson, MD, MPH
1.75 program credits

Clinical Practice

Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
- John Russell, MD
- Noel Dasgupta, MD, FACC
- Sami Khella, MD
0.50 credits
HF Management for Patients with Comorbid Conditions
HF Management for Patients with Comorbid Conditions
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 program credits
- Neil Skolnik, MD
- Barry Greenberg, MD
- Karina Brown, BSN, RN
- Jessica Lin, MPAP
- Melissa Mclenon, DNP, ACNP-BC
0.75 program credits
MinuteCE®
Optimizing Heart Failure Management
0.75 credits 5 episodes
- Brian P. McDonough, MD, FAAFP
- Barry Greenberg, MD
- Neil Skolnik, MD
- Trina Huynh, PharmD
- Jessica Lin, MPAP
- Melissa Mclenon, DNP, ACNP-BC
- Karina Brown, BSN, RN
0.75 credits 5 episodes
A Practical Guide to Prescribing in HF
A Practical Guide to Prescribing in HF
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 program credits
- Neil Skolnik, MD
- Barry Greenberg, MD
- Trina Huynh, PharmD
- Melissa Mclenon, DNP, ACNP-BC
0.75 program credits
How Artificial Sweeteners Could Be Linked to Heart Disease
How Artificial Sweeteners Could Be Linked to Heart Disease
Heart Matters
How Artificial Sweeteners Could Be Linked to Heart Disease
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Wilson Tang, MD
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
MinuteCE®
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
1.75 program credits
- Deborah Siegal, MD, MSc, FRCPC
1.75 program credits
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
MinuteCE®
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
1.75 program credits
- Deborah Siegal, MD, MSc, FRCPC
1.75 program credits
MinuteCE®
Primary Prevention, Initial Treatment & Management of VTE, Secondary VTE Prevention Strategies
1.75 credits 12 episodes
- Bruce L. Davidson, MD, MPH
- Scott Kaatz, DO, MSc, FACP, SFHM
- Deborah Siegal, MD, MSc, FRCPC
- Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
- Alfonso J. Tafur, MD, MS, MBA, RPVI
- Victor F. Tapson, MD
1.75 credits 12 episodes

CME

Level Up Your Skills: Tailoring Management of HF
Level Up Your Skills: Tailoring Management of HF
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 program credits
- Neil Skolnik, MD
- Barry Greenberg, MD
- Trina Huynh, PharmD
- Jessica Lin, MPAP
- Melissa Mclenon, DNP, ACNP-BC
- Karina Brown, BSN, RN
0.75 program credits
What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?
What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?
MinuteCE®
What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?
1.75 program credits
- Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
1.75 program credits
Case Time! V.T. Edwards: Management of Extended Thromboprophylaxis in the Medically Ill
Case Time! V.T. Edwards: Management of Extended Thromboprophylaxis in the Medically Ill
MinuteCE®
Case Time! V.T. Edwards: Management of Extended Thromboprophylaxis in the Medically Ill
1.75 program credits
- Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
1.75 program credits
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
MinuteCE®
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
1.75 program credits
- Alfonso J. Tafur, MD, MS, MBA, RPVI
1.75 program credits
Latest Guidance on Anticoagulation in Special AF Patient Populations
Latest Guidance on Anticoagulation in Special AF Patient Populations
MinuteCE®
Latest Guidance on Anticoagulation in Special AF Patient Populations
1.00 program credit
- Sean Pokorney, MD
1.00 program credit
How Do We Best Incorporate Latest Guidance in Optimizing Care for the Patient with AF?
How Do We Best Incorporate Latest Guidance in Optimizing Care for the Patient with AF?
MinuteCE®
How Do We Best Incorporate Latest Guidance in Optimizing Care for the Patient with AF?
1.00 program credit
- Sean Pokorney, MD
1.00 program credit
What Are the 10 Key Takeaways for the 2023 ACC/AHA/ACCP/HRS Guideline for AF?
What Are the 10 Key Takeaways for the 2023 ACC/AHA/ACCP/HRS Guideline for AF?
MinuteCE®
What Are the 10 Key Takeaways for the 2023 ACC/AHA/ACCP/HRS Guideline for AF?
1.00 program credit
- Manesh R. Patel, MD
1.00 program credit
What Are the Latest Updates on the Clinical and Economic Impact of AF?
What Are the Latest Updates on the Clinical and Economic Impact of AF?
MinuteCE®
What Are the Latest Updates on the Clinical and Economic Impact of AF?
1.00 program credit
- Sean Pokorney, MD
1.00 program credit